EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis

Eileen Galvani, Jeffrey A Cohen, John T Martin, Kunio Nakamura, Amy Kunchok, Rachel Galioto iD

Brain and Behavior · 2025

DOI: 10.1002/brb3.70310 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Eileen Galvani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Myelin-Oligodendrocyte Glycoprotein, Multiple Sclerosis, Cognitive Dysfunction, Cognition. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Consortium of Multiple Sclerosis Centers.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Little is known about cognitive outcomes in people with myelin oligodendrocyte glycoprotein‐IgG associated disease (pwMOGAD). While there are similarities between MOGAD and multiple sclerosis (MS), further evaluation is needed to establish the distinct cognitive trajectories for each disease.

Methods

Retrospective review of subjective cognitive changes was performed for adult pwMOGAD. Subsets of pwMOGAD completed a cognitive screening measure and/or comprehensive neuropsychological testing. Their performance was compared to age, sex, and race matched people with MS (pwMS; 3:1 ratio).

Results

Approximately half (51.6%) of pwMOGAD ( n = 63) endorsed cognitive dysfunction. On a cognitive screening measure (Processing Speed Test [PST]), performance did not statistically differ between pwMOGAD ( n = 36; M = −0.06, SD = 1.36) and pwMS ( n = 108; M = −0.04, SD = 1.30), t (62.35) = 0.18, p = 0.86. Of the pwMOGAD who completed neuropsychological testing (total n = 14), 57% demonstrated cognitive impairment on at least one test, and 36% demonstrated impairment on two or more tests. These rates did not differ from pwMS. In pwMOGAD, deficits were most common in processing speed (38.5%) and verbal fluency, spatial judgment, and immediate list recall (14.3% each). PwMOGAD performed better than pwMS on measures of visuomotor processing speed ( β = −0.378, t = −2.68, p = 0.01) and cognitive flexibility ( β = −0.33, t = −2.27, p = 0.03) after controlling for age, sex, race, education, and disease duration.

Conclusions

Subjective cognitive complaints and objective cognitive deficits were common among pwMOGAD. Approximately one‐third of pwMOGAD demonstrated clinically significant cognitive impairment (2+ tests impaired) and individual level deficits were most common on measures of processing speed, verbal fluency, spatial judgment, and word list recall.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelin-Oligodendrocyte GlycoproteinMultiple SclerosisCognitive DysfunctionCognitionHumansMaleFemaleMiddle AgedAdultRetrospective StudiesNeuropsychological TestsImmunoglobulin G

Stichwörter der Autor:innen

MOGADMyelin oligodendrocyte glycoprotein‐IgG associated diseasecognitive impairmentmultiple sclerosisneuropsychological test

Substanzen

Myelin-Oligodendrocyte GlycoproteinImmunoglobulin G

Autor:innen und Institutionen

  • Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Mellen Center for Multiple Sclerosis, Neurological Institute Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Psychological Sciences, Kent State University, Kent, Ohio, USA.
  • Department of Biomedical Engineering, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Rachel Galioto

Förderung

  • The Consortium of Multiple Sclerosis Centers

Zitieren

APA

Galvani, E., Cohen, J. A., Martin, J. T., Nakamura, K., Kunchok, A., & Galioto, R. (2025). Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis. Brain and Behavior. https://doi.org/10.1002/brb3.70310

Vancouver

Galvani E, Cohen JA, Martin JT, Nakamura K, Kunchok A, Galioto R. Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis. Brain and Behavior. 2025. doi:10.1002/brb3.70310

BibTeX
@article{Galvani2025,
  author = {Galvani, Eileen and Cohen, Jeffrey A and Martin, John T and Nakamura, Kunio and Kunchok, Amy and Galioto, Rachel},
  title = {Cognitive Outcomes in Myelin Oligodendrocyte Glycoprotein‐IgG Associated Disease Compared to Multiple Sclerosis},
  journal = {Brain and Behavior},
  year = {2025},
  doi = {10.1002/brb3.70310}
}
Kostenlos starten →